BayBridge Capital Group LLC Buys 13,821 Shares of Pfizer Inc. (NYSE:PFE)

BayBridge Capital Group LLC increased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 35.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 53,150 shares of the biopharmaceutical company's stock after acquiring an additional 13,821 shares during the period. BayBridge Capital Group LLC's holdings in Pfizer were worth $1,347,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of PFE. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the fourth quarter worth about $26,000. Clarity Asset Management Inc. acquired a new position in Pfizer during the 4th quarter worth approximately $27,000. Gould Capital LLC boosted its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the fourth quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $30,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PFE has been the subject of several analyst reports. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Cantor Fitzgerald started coverage on Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Price Performance

Shares of NYSE:PFE traded down $0.21 during trading hours on Monday, hitting $24.33. 11,152,078 shares of the company's stock traded hands, compared to its average volume of 41,094,796. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company's fifty day simple moving average is $23.06 and its two-hundred day simple moving average is $24.95. The company has a market cap of $138.31 billion, a price-to-earnings ratio of 17.25, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.82 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.07%. The ex-dividend date of this dividend was Friday, May 9th. Pfizer's payout ratio is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.